Uterine cancer
Last update
There were 765 new cases of cervical cancer registered in Norway in 2024. In many cases, the disease is detected early, which increases the chances of curing it. Nearly 86 percent survive their cancer for five years or more.
About uterine cancer
Uterine cancer occurs in the body of the uterus and belongs to the group of gynecological cancers, but must not be confused with cervical cancer.
Cancer of the uterus is mostly seen in women who have reached menopause and the first symptom is often bleeding after menstruation has stopped.
A distinction is made between cancer that arises in the uterine lining (the endometrium) and cancer that originates in the muscles of the uterine wall (the myometrium).
Cancer that starts from the lining of the uterus (endometrial cancer) is the most common form of cancer in the uterus, and the sixth most common form of cancer in women in Norway. Cancer originating from muscles (sarcoma) is a rare form of cancer in the uterus.
Source: kreftlex.no
Key figures uterine cancer 2024
New cases
765
Rates - number of cases per 100,000
23.5
5-year relative survival (2020-2024)
85.5 %
Cancer survivors
12,089 people as of 31.12.2024
Deaths (2023)
111
Cumulative risk of developing uterine cancer by age 80 (2020-2024)
2.2 %
Risk factors
Lifestyle factors
- Overweight/obesity and physical inactivity increase the risk of uterine cancer
Other factors
- Increased risk has been shown for women who have had few or no children, and at late menopause
- Estrogen increases the risk, estrogen supplements are therefore normally only given to women who have had their uterus removed. Birth control pills and hormone therapy for menopausal women containing estrogen and progesterone, or only progesterone, provide a protective effect
Measures you can take to reduce your risk of getting uterine cancer
- Maintain a healthy body weight, avoid overweight and obesity
- Be physically active
Questions about cancer
The Cancer Registry of Norway is a research institution. Our professionals therefore do not answer questions about diagnosis, assessment, treatment and follow-up from patients or their relatives.
Inquiries about this information should be directed to your general practitioner, treating institution, or the Norwegian Cancer Society's advisory service at phone: +47 21 49 49 21.